Merck plans trio of Phase 3 Keytruda studies in prostate cancer
Merck & Co. said Thursday it plans to launch three pivotal Phase 3 studies testing different combination therapies involving its blockbuster immunotherapy Keytru...
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.